Inhaled corticosteroids for bronchiectasis

Cochrane Database of Systematic Reviews

Volumn 2018, Issue 5, 2018, Pages

  Kapur, Nitin ^a,b   Petsky, Helen L ^c   Bell, Scott ^d   Kolbe, John ^e   Chang, Anne B ^f,g  

^a LADY CILENTO CHILDREN S HOSPITAL   (Australia)

^b UNIVERSITY OF QUEENSLAND   (Australia)

^c GRIFFITH UNIVERSITY   (Australia)

^d THE PRINCE CHARLES HOSPITAL   (Australia)

^e THE UNIVERSITY OF AUCKLAND   (New Zealand)

^f MENZIES SCHOOL OF HEALTH RESEARCH   (Australia)

^g QUEENSLAND UNIVERSITY OF TECHNOLOGY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; ANDROSTANE DERIVATIVE; ANTIINFECTIVE AGENT; BECLOMETASONE; FLUTICASONE;

ADVERSE OUTCOME; BRONCHIECTASIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMPUTER ASSISTED TOMOGRAPHY; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DYSPNEA; EFFECT SIZE; EOSINOPHILIA; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HUMAN; INTENTION TO TREAT ANALYSIS; LUNG FUNCTION; POPULATION RESEARCH; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUALITY OF LIFE; RELIABILITY; RESPIRATORY TRACT INFECTION; REVIEW; RISK ASSESSMENT; SCORING SYSTEM; SPUTUM; SYSTEMATIC REVIEW; TREATMENT OUTCOME; ADULT; INHALATIONAL DRUG ADMINISTRATION; LUNG FUNCTION TEST; META ANALYSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); VITAL CAPACITY;

ADMINISTRATION, INHALATION; ADRENAL CORTEX HORMONES; ADULT; ANDROSTADIENES; ANTI-BACTERIAL AGENTS; BECLOMETHASONE; BRONCHIECTASIS; DISEASE PROGRESSION; FLUTICASONE; FORCED EXPIRATORY VOLUME; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESPIRATORY FUNCTION TESTS; VITAL CAPACITY;

EID: 84891702089     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD000996.pub3     Document Type: Review

References (71)

1. Elborn JS, Johnston B, Allen F, Clarke J, McGarry J, Varghese G. Inhaled steroids in patients with bronchiectasis. Respiratory Medicine 1992;86(2):121-4. [PUBMED: 1615177]8395245
2. Hernando R, Drobnic ME, Cruz MJ, Ferrer A, Sune P, Montoro JB, et al. Budesonide efficacy and safety in patients with bronchiectasis not due to cystic fibrosis. International Journal of Clinical Pharmacy 2012;34:644-50. 8395247
3. Joshi JM, Sundaram P. Role of inhaled steroids in stable bronchiectasis. Indian Practitioner 2004;57(4):243-5. 8395249
4. Martinez Garcia MA, Perpina-Tordera M, Roman-Sanchez P, Soler-Cataluna JJ. Inhaled steroids improve quality of life in patients with steady state bronchiectasis. Respiratory Medicine 2006;100:1623-32. 8395251
5. Tsang KW, Ho P, Lam W, Ip M, Chan K, Ho C, et al. Inhaled fluticasone reduces sputum inflammatory indices in severe bronchiectasis. American Journal of Respiratory and Critical Care Medicine 1998;158(3):723-7. [PUBMED: 9730996]8395253
6. Tsang KW, Tan KC, Ho PL, Ooi GC, Khong PL, Leung R, et al. Exhaled nitric oxide in bronchiectasis: the effects of inhaled corticosteroid therapy. International Journal of Tuberculosis and Lung Disease 2004;8(11):1301-7. 8395255
7. Tsang KW, Tan KC, Ho PL, Ooi GC, Ho JC, Mak J, et al. Inhaled fluticasone in bronchiectasis: a 12-month study. Thorax 2005;60:239-43. [PUBMED: 15741443]8395257
8. Ghosh CS, Joseraj R, Kumari A, Jayaprakash. A randomized controlled clinical trial comparing the effects of inhaled budesonide vs inhaled ipratropium in patients with bronchiectasis. Indian Journal of Allergy Asthma and Immunology 2002;16(1):55-71. 8395259
9. Guran T, Ersu R, Karadag B, Karakoc F, Demirel Y, Hekim N, et al. Withdrawal of inhaled steroids in children with non-cystic fibrosis bronchiectasis. Journal of Clinical Pharmacy and Therapeutics 2008;33:603-11. 8395261
10. Martinez-Garcia MA, Soler-Cataluna JJ, Catalan-Serra P, Roman-Sanchez P, Tordera MP. Clinical efficacy and safety of budesonide-formoterol in non-cystic fibrosis bronchiectasis. Chest 2012;141(2):461-8. 8395263
11. Monton C, Ewig S, Torres A, El-Ebiary M, Filella X, Rano A, et al. Role of glucocorticoids on inflammatory response in non-immunosuppressed patients with pneumonia: a pilot study. European Respiratory Journal 1999;14:218-20. 8395265
12. O'Neill B, Bradley JM, Macmohan J, Elborn S. Subjective benefit of inhaled therapies in patients with bronchiectasis: a questionnaire study. International Journal of Clinical Practice 2004;58(5):441-3. 8395267
13. Balfour-Lynn IM, Lees B, Hall P, Phillips G, Khan M, Flather M, et al. Multicenter randomized controlled trial of withdrawal of inhaled corticosteroids in cystic fibrosis. American Journal of Respiratory and Critical Care Medicine 2006;173(12):1356-62.
14. Balfour-Lynn I, Welch K. Inhaled corticosteroids for cystic fibrosis. Cochrane Database of Systematic Reviews 2014, Issue 10. [DOI: 10.1002/14651858.CD001915]
15. Barnes PJ. Inhaled corticosteroids. Pharmaceuticals (Basel) 2010;3(3):514-40.
16. Berend N, Salome CM, King GG. Mechanisms of airway hyperresponsiveness in asthma. Respirology 2008;13:624-31.
17. Booth H, Richmond I, Ward C, Gardiner PV, Harkawat R, Walters EH. Effect of high dose inhaled fluticasone propionate on airway inflammation in asthma. Americal Journal of Respiratory and Critical Care Medicine 1995;152(1):45-52.
18. Cates C. Visual Rx. Online NNT Calculator. Dr Christopher Cates, 2008.
19. Chang AB, Grimwood K, Mulholland EK, Torzillo PJ. Bronchiectasis in Indigenous children in remote Australian communities. Medical Journal of Australia 2002;177(4):200-4.
20. Chang AB, Bilton D. Exacerbations in cystic fibrosis: 4-non-cystic fibrosis bronchiectasis. Thorax 2008;63(3):269-76.
21. Chang AB, Bell SC, Byrnes CA, Grimwood K, Holmes PW, King PT, et al. Chronic suppurative lung disease and bronchiectasis in children and adults in Australia and New Zealand. Medical Journal of Australia 2010;193:356.
22. Chang AB, Bell SC, Torzillo PJ, King PT, Byrnes CA, Maguire GP, et al. Bronchiectasis and chronic suppurative lung disease (CSLD) in children and adults in Australia and New Zealand: Thoracic Society of Australia and New Zealand Guideline: an update. Medical Journal of Australia 2015;202:21-3.
23. Cole PJ. Inflammation: a two edged sword. The model of bronchiectasis. European Journal of Respiratory Disease. Supplement 1986;147:6-15.
24. Daniel S, Jose O. A study on HbA1c profile in children with asthma using inhaled corticosteroids. International Journal of Contemporary Pediatrics 2017;4(3):796-800. [DOI: http://dx.doi.org/10.18203/2349-3291.ijcp20171489]
25. Edwards EA, Asher MI, Byrnes CA. Paediatric bronchiectasis in the twenty-first century: experience of a tertiary children's hospital in New Zealand. Journal of Paediatrics and Child Health 2003;39(2):111-7.
26. Elbourne DR, Altman DG, Higgins JP, Curtin F, Worthington HV, Vail A. Meta-analyses involving cross-over trials: methodological issues. International Journal of Epidemiology 2002;31(1):140-9.
27. Ellerman A, Bisgaard H. Longitudinal study of lung function in a cohort of primary ciliary dyskinesia. European Respiratroy Journal 1997;10(10):2376-9.
28. Ernst P, Saad N, Suissa S. Inhaled corticosteroids in COPD: the clinical evidence. European Respiratory Journal 2015;45(2):525-37. [DOI: 10.1183/09031936.00128914]
29. Festic E, Bansal V, Gupta E, Scanlon PD. Association of inhaled corticosteroids with incident pneumonia and mortality in COPD patients; systematic review and meta-analysis. COPD 2016;13(3):312-26. [DOI: 10.3109/15412555.2015.1081162]
30. Field CE. Bronchiectasis. Third report on a follow-up study of medical and surgical cases from childhood. Archives of Disease in Childhood 1969;44(237):551-61.
31. Finch S, McDonnell MJ, Abo-Leyah H, Aliberti S, Chalmers JD. A comprehensive analysis of the impact of pseudomonas aeruginosa colonization on prognosis in adult bronchiectasis. Annals of the American Thoracic Society 2015;12(11):1602-11.
32. Goyal V, Grimwood K, Masters IB, Marchant JM, Chang AB. State of the art: pediatric bronchiectasis - no longer an orphan disease. Pediatric Pulmonology 2016;51(5):450-69.
33. McMaster University (developed by Evidence Prime). GRADEpro GDT. Version accessed prior to 30 April 2018. Hamilton (ON): McMaster University (developed by Evidence Prime), 2015.
34. Guan WJ, Gao YH, Xu G, Lin ZY, Tang Y, Li HM, et al. Characterization of lung function impairment in adults with bronchiectasis. PLoS ONE 2014;9(11):e113373. [DOI: 10.1371/journal.pone.0113373]
35. Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
36. Holme J, Tomlinson JW, Stockley RA, Stewart PM, Barlow N, Sullivan AL. Adrenal suppression in bronchiectasis and impact of inhaled corticosteroids. European Respiratory Journal 2008;32:1047-52.
37. Ip M, Lam WK, Liong E, Chan CY, Tse KM. Analysis of factors associated with bronchial hyperreactivity to methacholine in bronchiectasis. Lung 1991;169(4):245.
38. Ip M, Lauder IJ, Wong WY. Multivariate analysis of factors affecting pulmonary function in bronchiectasis. Respiration 1993;60:45-50.
39. Kapur N, Masters IB, Chang AB. Exacerbations in noncystic fibrosis bronchiectasis: Clinical features and investigations. Respiratory Medicine 2009;103:1681.
40. Kapur N, Masters IB, Chang AB. Longitudinal growth and lung function in pediatric non-CF bronchiectasis - what influences lung function stability?. Chest 2010;138:158.
41. Kapur N, Masters IB, Newcombe P, Chang AB. The burden of disease in paediatric non-cystic fibrosis bronchiectasis. Chest 2012;141:1018.
42. Kapur N, Masters IB, Morris PS, Galligan J, Ware R, Chang AB. Defining pulmonary exacerbation in children with non-cystic fibrosis bronchiectasis. Pediatric Pulmonology 2012;47(1):68.
43. Karadag B, Karakoc F, Ersu R, Kut A, Bakac S, Dagli E. Non-cystic-fibrosis bronchiectasis in children: a persisting problem in developing countries. Respiration 2005;72(3):233-8.
44. Karakoc GB, Yilmaz M, Altintas DU, Kendirli SG. Bronchiectasis: still a problem. Pediatric Pulmonology 2001;32(2):175-8.
45. Keistinen T, Saynajakangas O, Tuuponen T, Kivela SL. Bronchiectasis: an orphan disease with a poorly-understood prognosis. European Respiratory Journal 1997;10(12):2784-7.
46. Kerstjens HA, Postma DS, van Doormaal JJ, van Zanten AK, Brand PL, Dekhuijzen PN, et al. Effects of short-term and long-term treatment with inhaled corticosteroids on bone metabolism in patients with airways obstruction. Dutch CNSLD Study Group. Thorax 1994;49(7):652-6.
47. Kim V, Rogers TJ, Criner GJ. New concepts in the pathobiology of chronic obstructive pulmonary disease. Proc Am Thorac Soc 2008 May 1;5(4):478-85.
48. Lee C, Klaustermeyer WB. Effect of high dose inhaled corticosteroids on cell mediated immunity in patients with asthma. Allergologia et Immunopathologia (Madr) 2012;40(2):100-3.
49. Mandal P, Hill AT. Bronchiectasis: breaking the cycle of inflammation and infection. Lancet Respiratory Medicine 2013;1:e5-6.
50. Olveira C, Padilla A, Martínez-García MÁ, de la Rosa D, Girón RM, Vendrell M, et al. Etiology of bronchiectasis in a cohort of 2047 patients. An analysis of the Spanish Historical Bronchiectasis Registry. Archivos Bronconeumologia 2017;53(7):366-74.
51. Pasteur MC, Bilton D, Hill AT. British Thoracic Society guideline for non-CF bronchiectasis. Thorax 2010;65 (Suppl 1):i1-i58.
52. Philip J. The effects of inhaled corticosteroids on growth in children. Open Respiratory Medicine Journal 2014;8(Suppl 1:M3):66-73.
53. Pizzutto SJ, Grimwood K, Bauert P, Schultz KL, Yerkovich ST, Upham JW, et al. Flexible bronchoscopy contributes to the clinical management of Indigenous children with non-cystic fibrosis bronchiectasis. Pediatric Pulmonology 2013;48:67-73.
54. Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Annals of Internal Medicine 2009;151(4):264-9.
55. Pruteanu AI, Chauhan BF, Zhang L, Prietsch SO, Ducharme FM. Inhaled corticosteroids in children with persistent asthma: dose-response effects on growth. Cochrane Database of Systematic Reviews 2014, Issue 7. [DOI: 10.1002/14651858.CD009878.pub2]
56. Renkema TE, Schouten UP, Koeter GH, Postma DS. Effects of long-term treatment with corticosteroids in COPD. Chest 1996;109(5):1156-62.
57. Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
58. Sabroe I, Postma D, Heijink I, Dockrell DH. The yin and the yang of immunosuppression with inhaled corticosteroids. Thorax 2013;68(12):1085-7. [DOI: 10.1136/thoraxjnl-2013-203773]
59. Sánchez-Muñoz G, López de Andrés A, Jiménez-García R, Carrasco-Garrido P, Hernández-Barrera V, Pedraza-Serrano F, et al. Time trends in hospital admissions for bronchiectasis: analysis of the Spanish national hospital discharge data (2004 to 2013). PLoS One 2016;11(9):e0162282.
60. Shoemark A, Ozerovitch L, Wilson R. Aetiology in adult patients with bronchiectasis. Respiratory Medicine 2007;101(6):1163-70.
61. Singleton R, Morris A, Redding G, Poll J, Holck P, Martinez P, et al. Bronchiectasis in Alaskan Native children: causes and clinical courses. Pediatric Pulmonology 2000;29(3):182-7.
62. Sobieraj DM, White CM, Coleman CI. Benefits and risks of adjunctive inhaled corticosteroids in chronic obstructive pulmonary disease: a meta-analysis. Clinical Therapeutics 2008;30(8):1416-25.
63. Tsikrika S, Dimakou K, Papaioannou AI, Hillas G, Thanos L, Kostikas K, et al. The role of non-invasive modalities for assessing inflammation in patients with non-cystic fibrosis bronchiectasis. Cytokine 2017;99:281-6.
64. Twiss J, Stewart AW, Byrnes CA. Longitudinal pulmonary function of childhood bronchiectasis and comparison with cystic fibrosis. Thorax 2006;61(5):414-8.
65. van Haren EH, Lammers JW, Festen J, Heijerman HG, Groot CA, van Herwaarden CL. The effects of inhaled corticosteroid budesonide on lung function and bronchial hyper-responsiveness in adult patients with cystic fibrosis. Respiratory Medicine 1995;89:209-14.
66. Wang CY, Lai CC, Yang WC, Lin CC, Chen L, Wang HC, et al. The association between inhaled corticosteroid and pneumonia in COPD patients: the improvement of patients' life quality with COPD in Taiwan (IMPACT) study. International Journal of Chronic Obstructive Pulmonary Disease 2016;11:2775-83.
67. Wilson CB, Jones PW, O'Leary CJ, Cole PJ, Wilson R. Validation of the St. George's Respiratory Questionnaire in bronchiectasis. American Journal of Respiratory and Critical Care Medicine 1997;156:536-41.
68. Yang IA, Clark MS, Sim EH, Fong KM. Inhaled corticosteroids for stable chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews 2012, Issue 7. [DOI: 10.1002/14651858.CD002991.pub3]
69. Kapur N, Bell S, Kolbe J, Chang AB. Inhaled steroids for bronchiectasis. Cochrane Database of Systematic Reviews 2009, Issue 1. [DOI: 10.1002/14651858.CD000996.pub2]
70. Kolbe J, Wells A. Inhaled steroids in the treatment of bronchiectasis. Cochrane Database of Systematic Reviews 1998, Issue 1. [DOI: 10.1002/14651858.CD000996]
71. Kolbe J, Wells A, Ram FS. Inhaled steroids for bronchiectasis. Cochrane Database of Systematic Reviews 2000, Issue 2. [DOI: 10.1002/14651858.CD000996]